KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Current Leases (2019 - 2025)

Historic Current Leases for Arbutus Biopharma (ABUS) over the last 12 years, with Q3 2025 value amounting to $531000.0.

  • Arbutus Biopharma's Current Leases rose 1346.15% to $531000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $531000.0, marking a year-over-year increase of 1346.15%. This contributed to the annual value of $483000.0 for FY2024, which is 1364.71% up from last year.
  • Per Arbutus Biopharma's latest filing, its Current Leases stood at $531000.0 for Q3 2025, which was up 1346.15% from $514000.0 recorded in Q2 2025.
  • Arbutus Biopharma's Current Leases' 5-year high stood at $563000.0 during Q1 2025, with a 5-year trough of $357000.0 in Q2 2021.
  • Its 5-year average for Current Leases is $436842.1, with a median of $432000.0 in 2021.
  • Per our database at Business Quant, Arbutus Biopharma's Current Leases crashed by 673.58% in 2022 and then skyrocketed by 1444.44% in 2023.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Current Leases stood at $383000.0 in 2021, then decreased by 2.87% to $372000.0 in 2022, then grew by 14.25% to $425000.0 in 2023, then increased by 13.65% to $483000.0 in 2024, then grew by 9.94% to $531000.0 in 2025.
  • Its Current Leases stands at $531000.0 for Q3 2025, versus $514000.0 for Q2 2025 and $563000.0 for Q1 2025.